Table 2 Baseline characteristics of the included patient cohorts and controls

From: Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series

Cohort

Total N

Male (%)

Mean AAO

Early onset (%)

Goldman score

Site of sample origin

1

2

3

3.5

4

4.5

NHNN cognitive centre

NHS cognitive disorder clinics

National prion clinic

NHNN Clinical neurogenetics

Cardiff university

AD

1052

400 (38.0%)

57.7

78

73 (6.9%)

30 (2.9%)

66 (6.3%)

103 (9.8%)

245 (23.3%)

535 (50.9%)

873 (83.0%)

103 (9.8%)

1 (0.1%)

75 (7.1%)

0

FTD

794

419 (52.8%)

58.4

61

72 (9.1%)

43 (5.4%)

50 (6.3%)

64 (8.1%)

298 (37.5%)

267 (33.6%)

645 (81.2%)

45 (5.7%)

0

104 (13.1%)

0

Prion

299

121 (40.5%)

57.6

55

34 (11.4%)

6 (2.0%)

11 (3.7%)

15 (5.0%)

207 (69.2%)

26 (8.7%)

2 (0.7%)

0

296 (99.0%)

1 (0.3%)

0

DemMot

639

280 (43.8%)

55.8

70

24 (3.8%)

12 (1.9%)

18 (2.8%)

84 (13.2%)

215 (33.7%)

286 (44.8%)

535 (83.7%)

17 (2.7%)

0

87 (13.6%)

0

Controls

457

237 (51.9%)

76.6

–

4 (0.9%)

0

0

2 (0.4%)

0

451 (98.7%)

6 (1.3%)

0

3 (0.7%)

0

448 (98.0%)

All

3241

1457 (45.0%)

60.3

59

207 (6.4%)

91 (2.8%)

145 (4.5%)

268 (8.3%)

965 (29.8%)

1565 (48.3%)

2061 (63.6%)

165 (5.1%)

300 (9.3%)

267 (8.2%)

448 (13.8%)

  1. The 3241 samples were made up by 1052 AD patients, 794 FTD patients, 299 prion patients and 639 patients with dementia with motor symptoms, as well as 457 elderly controls. This table shows the distribution of each cohort in numbers and percentages for their baseline characteristics sex, age at onset (AAO), early- or late-onset disease (over or under 65 AAO), Goldman score [30] and the site of the sample origin, i.e., whether it was a retrospective sample chosen from the collection of a cognitive centre, a prospectively recruited sample from a Memory Clinic at a primary referral centre, a sample from the National Prion Clinic or a control sample
Back to article page